Search Contract Opportunities

Enhancing the CDC Autocidal Gravid Ovitrap to control dengue vectors.

ID: CDC/NCEZID 037 • Type: SBIR / STTR Topic • Match:  95%
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Please sign-in to link federal registration and award history to assistant. Sign in to upload a capability statement or catalogue for your company

Some suggestions:
Please summarize the work to be completed under this opportunity
I'd like to anonymously submit a question to the procurement officer(s)
Loading

Description

Phase I SBIR proposals will be accepted. Fast-track proposals will not be accepted. Phase I clinical trials will not be accepted. Number of anticipated awards: 1 Budget (total costs): Phase I up to $243,500 for up to 6 months; Phase II of up to $2,045,816 and a Phase II duration of up to 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Background: Dengue is an increasing public health threat with outbreaks occurring globally, including in US territories. Traditional vector control methods have limited impact due to widespread insecticide resistance and resource intensive and unsustainable community engagement and source reduction. CDC developed, tested, and patented the Autocidal Gravid Ovitrap for the surveillance and control of Aedes aegypti, the main mosquito vector of dengue and other arboviruses (Barrera et al. 2024). This trap captures mosquitoes by means of a special sticky glue. It does not use insecticides. CDC produced evidence showing how useful AGO traps are for the surveillance and effective control of this vector (Barrera et al. 2017, 2018, 2019, 2020). A previous SBIR took the trap prototype to a mass production product that was commercialized. Mass trapping with AGO traps reduces the abundance of Ae. aegypti populations. A count of 3 or fewer mosquitoes per trap has been proposed as a threshold to reduce transmission of arboviruses in Puerto Rico. In neighborhoods with 2 to 3 traps per house in 80% of the houses, mosquito counts were maintained below the threshold. The AGO traps have been shown to reduce chikungunya transmission, Zika transmission, and mosquitoes infected with dengue (Sharp et al. 2019; CDC unpublished). AGO traps need to be serviced every 2-3 months to replace water, attractant (a small pack of regular hay grass that decomposes in the water), and a sticky board, and where mosquitoes are caught when they land inside the trap chamber to lay their eggs. When thousands of these traps are deployed in communities for the area-wide control of Ae. aegypti, many operators are needed to complete the maintenance cycle. To involve the community in servicing the traps, it would be required the trap to be easily and quickly maintained by residents. The trap could be improved by 1- producing a disposable capture chamber that residents could easily replace, as opposed to the current model that requires handling the sticky board with the dead mosquitoes and stripping away the rest of glue, 2- ideally, replacing by hay pack with a synthetic attractant that would last 2-3 months, and 3- producing an effective sticky glue. The latter is important since the current sticky glue is produced by just one company, and it is a major limitation for the use of AGO traps because of its limited production and distribution.

Overview

Agency
None Found
Response Deadline
Oct. 18, 2024 Past Due
Posted
Aug. 2, 2024
Open
Aug. 2, 2024
Set Aside
Small Business (SBA)
NAICS
None
PSC
None
Place of Performance
Not Provided
Source
Alt Source
Program
SBIR Phase I / II
Structure
None
Phase Detail
Phase I: Establish the technical merit, feasibility, and commercial potential of the proposed R/R&D efforts and determine the quality of performance of the small business awardee organization.
Phase II: Continue the R/R&D efforts initiated in Phase I. Funding is based on the results achieved in Phase I and the scientific and technical merit and commercial potential of the project proposed in Phase II. Typically, only Phase I awardees are eligible for a Phase II award
Duration
6 Months - 1 Year
Size Limit
500 Employees
On 8/2/24 issued SBIR / STTR Topic CDC/NCEZID 037 for Enhancing the CDC Autocidal Gravid Ovitrap to control dengue vectors. due 10/18/24.

Documents

Posted documents for SBIR / STTR Topic CDC/NCEZID 037

Question & Answer

The AI Q&A Assistant has moved to the bottom right of the page

Contract Awards

Prime contracts awarded through SBIR / STTR Topic CDC/NCEZID 037

Incumbent or Similar Awards

Potential Bidders and Partners

Awardees that have won contracts similar to SBIR / STTR Topic CDC/NCEZID 037

Similar Active Opportunities

Open contract opportunities similar to SBIR / STTR Topic CDC/NCEZID 037